Evidence mounts for addition of SGLT2i to CKD treatment regimen

A panel of distinguished speakers discuss chronic kidney disease (CKD) and the role of a sodium/glucosecotransporter-2 inhibitor (SGLT2i) newly indicated for the treatment of patients with CKD during a Boehringer Ingelheim sponsored symposium in Kuala Lumpur.